Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved patient-reported outcomes.